In patients with early PKD, dual blockage of the RAS system provided no advantage over ACE inhibitor alone. Patients targeted to the standard blood pressure target (120/70 to 130/80 mm Hg) vs a low blood-pressure target (95/60 to 110/75 mm Hg) had reduced annual % increase in total kidney volume (6.6% vs. 5.6%, P=0.006) and more reduction in urinary albumin excretion (3.77% vs 2.43% , P<0.001). However, there was no difference in rate of change in estimated GFR.
- Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
- Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials
- Systematic Review: Blood Pressure Target in Chronic Kidney Disease and Proteinuria as an Effect Modifier